A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
Phase 3
Terminated
- Conditions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 33
- Registration Number
- NCT00287742
An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 52
- Registration Number
- NCT00257023
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 205
- Registration Number
- NCT00240708
Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 74
- Registration Number
- NCT00216645
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 13
- Registration Number
- NCT00216697
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 139
- Registration Number
- NCT00216684
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 87
- Registration Number
- NCT00216658
© Copyright 2024. All Rights Reserved by MedPath